Platelet morphology and plasma indices of platelet activation in essential hypertension: effects of amlodipine-based antihypertensive therapy

References

• Nadar S, Lip GYH. The prothrombotic state in hypertension and the effects of antihypertensive treatment. Curr Pharm Des
   Google Scholar
• Schmeider RE, Messerli FH. Hypertension and the heart. J Hum Hypertens 2000;14:597–604.
   PubMed Web of Science ®Google Scholar
• Blann AD, Nadar S, Lip GYH. Pharmacological modulation patients with mild to moderate hypertension. Int J Clin Pharmacol Ther 1999;37:323–31.
   Google Scholar
• Hernandez-Hernandez R, Armas-Padilla MC, Velasco M, Carvajal AR, Armas de Hernandez MJ, Guerrero-Pajuelo J, et al. Effects of amlodipine and enalapril on platelet function inpatients with mild to moderate hypertension. Int J Clin Pharmacol Ther 1999;37:323–31.
   Google Scholar
• Pirich C, Schmid P, Fitscha P, Wytek R, O'Grady J, Sinzinger H. Influence of calcium antagonists on platelet function and vascular prostacyclin production. Blood Press Suppl 1994;1: 75–80.
   Google Scholar
• Rink TJ, Sage SO. Calcium signalling in human platelets. Annu Rev Physiol 1990;52:431–49.
   PubMed Web of Science ®Google Scholar
• Islim IF, Beevers DG, Bareford D. The effect of antihyperten-sive drugs on in vivo platelet activation in essential hyper-tension. J Hypertens 1992;10:379–83.
   Google Scholar
• Gleerup G, Vind J, Winther K. Platelet function and fibrinolytic activity during rest and exercise in borderline hypertensive patients. Eur J Clin Invest 1995;25:266–70.
   Google Scholar
• Yamamshi J, Sano H, Saito K, Furuta Y, Fukuzaki H. Plasma concentrations of platelet specific proteins in different stages of essential hypertension: interactions between platelet aggre�gation, blood lipids and age. Thromb Haemostasis 1985;54: 539–43.
   Google Scholar
• Lip GYH, Blann AD, Zarifis J, Beevers M, Lip PL, Beevers DG. Soluble adhesion molecules P-selectin, and endothelial dysfunction in essential hypertension: implications for athero-genesis? A preliminary report. J Hypertens 1995;13:1674–8.
   PubMed Web of Science ®Google Scholar
• Lande K, Os I, Kjeldsen SE, Westheim A, Hjermann I, Ride I, et al. Increased platelet size and release reaction in essential hypertension. J Hypertens 1987;5:401–6.
   PubMed Web of Science ®Google Scholar
• Kamath S, Blann AD, Came GJ, Gurney D, Chin BS, Lip GYH. Platelet P-selectin levels in relation to plasma soluble P-selectin and beta-thromboglobulin levels in atrial fibrilla�tion. Stroke 2002;33:1237–42.
   PubMed Web of Science ®Google Scholar
• Smith A, McPherson J, Taylor M, Mason A, Carney S, Gilles A. Pro-haemorrhagic effects of calcium antagonists: a com-parison of isradipine and atenolol on ex-vivo platelet function in hypertensive patients. J Hum Hypertens 1997;11:783–8.
   PubMed Web of Science ®Google Scholar
• Ranieri G, Filitti V, Andriam A, Bonfantino MV, Lamonta-nara G, Cavallo A, et al. Effects of isradipine sustained release on platelet function and fibrinolysis in essential hypertensives with or without other risk factors. Cardiovasc Drugs Ther 1996;10:119–23.
   Google Scholar
• Lip GYH, Edmunds E, Li Saw Hee FL, Blann AD, Beevers DG. A cross-sectional, diurnal and follow-up study of platelet activation and endothelial dysfunction in malignant phase hypertension. Am J Hypertens 2001;14:823–8.
   Google Scholar
• Gomi T, Ikeda T, Shibuya Y, Nagao R. Effects of antihyper-tensive treatment on platelet function in essential hyperten-sion. Hypertens Res 2000;23:567–72.
   PubMed Web of Science ®Google Scholar
• Endler G, Klimesch A, Sunder-Plassmann H, Schillinger M, Exner M, Mannhalter C, et al. Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease. Br J Haematol 2002;117:399–404.
   Google Scholar
• Martin JF, Bath PM, Burr ML. Influence of platelet size on outcome after myocardial infarction. Lancet 1991;338:1409–11.
   Google Scholar
• Kennon S, Price CP, Mills PG, Macey M, Cooper J, Clarke H, et al. The central role of platelet activation in determining the severity of acute coronary syndromes. Heart 2003;89:1253–4.
   PubMed Web of Science ®Google Scholar
• Yilmaz MB, Ozeke 0, Akin Y, Guray U, Biyikoglu SF, Kisacik HL, et al. Platelet aggregation in left ventricular thrombus formation after acute anterior myocardial infarction: mean platelet volume. Int J Cardiol 2003;90: 123–5.
   Google Scholar
• Bath PM, Carney C, Markandu ND, MacGregor GA. Platelet volume is not increased in essential hypertension. J Hum Hypertens 1994;8:457–9.
   PubMed Web of Science ®Google Scholar
• Bath PM, Missouris CG, Buckenham T, MacGregor GA. Increased platelet volume and platelet mass in patients with atherosclerotic renal artery stenosis. Clin Sci 1994;87:253-7. Basara N, Jerkic M, Susic D, Pavlovic-Kentera V. Megakaryo-cytopoiesis in spontaneously hypertensive rats (SHR). Thromb Res 1989;53: 551–9.
   Google Scholar
• Basara N, Jerkic M, Susie D, Pavlovic-Kentera V. Megakaryo-cytopoiesis in spontaneously hypertensive rats (SHR). Thromb Res 1989;53:551–9.
   Google Scholar
• Pathansali R, Smith NM, Bath PM. Prothrombotic mega-karyocyte and platelet changes in hypertension are reversed following treatment: a pilot study. Platelets 2001;12:144-9. Fasolato C, Innocenti B, Pozzan T. Receptor activated calcium influx: how many mechanisms for how many channels. Trends Pharmacol Sci 1994;15: 77–83.
   Google Scholar
• Fasolato C, Innocenti B, Pozzan T. Receptor activated calcium influx: how many mechanisms for how many channels. Trends Pharmacol Sci 1994;15:77–83.
   Google Scholar
• Ryback MEM, Renzulli LA. Effect of calcium channel blockers on platelet GpIIb-IIIa as a calcium channel in lipo-somes: comparison with effects on the intact platelets. Thromb Haemost 1992;67:131–6.
   PubMed Web of Science ®Google Scholar
• Taddei S, Virdis A, Ghiadoni L, Uleri S, Magagna A, Salvetti A. Lacidipine restores endothelium-dependent vasodilation in essential hypertensive patients. Hypertension 1997; 30: 1606–12.
   PubMed Web of Science ®Google Scholar
• Megnien JL, Levenson J, Del Pino M, Simon A. Amlodipine induces a flow and pressure-independent vasoactive effect on the brachial artery in hypertension. Br J Clin Pharmacol 1995; 39:641–9.
   PubMed Web of Science ®Google Scholar
• Schiffrin EL, Pu Q, Park JB. Effect of amlodipine compared to atenolol on small arteries of previously untreated essential hypertensive patients. Am J Hypertens 2002;15:105–10.
   Google Scholar
• Chou TC, Li CY, Yen MH, Ding YA. Antiplatelet effect of amlodipine: a possible mechanism through a nitric oxide-mediated process. Biochem Pharmacol 1999;58:1657-63. Hernandez R, Carvajal AR, Armas-de Hernandez MJ, Guerrero-Pajuelo J, Armas-Padilla MC, Barragan 0, et al. Effects of amlodipine on platelet aggregation and blood pressure in patients with essential hypertension. Clin Ther 1993;15: 304–13.
   Google Scholar
• Hernandez R, Carvajal AR, Armas-de Hernandez MJ, Guerrero-Pajuelo J, Armas-Padilla MC, Barragan 0, et al. The effects of the calcium antagonist amlodipine on blood pressure and platelet aggregation in hypertensive patients. Postgrad Med J 1991;67\(Suppl 5)S38–S40.
   Google Scholar
• Hernandez R, Carvajal AR, Armas-de Hernandez MJ, Guerrero-Pajuelo J, Armas-Padilla MC, Barragan O, et al. The effects of the calcium antagonist amlodipine on blood pressure and platelet aggregation in hypertensive patients. Postgrad Med J 1991;67\(Suppl 5)S38–S40.
   Google Scholar
• Kiyomoto A, Sasaki Y, Odawara A, Morita T. Inhibition of platelet aggregation by diltiazem. Comparison with verapamil and nifedipine and inhibitory potencies of diltiazem metab-olites. Circ Res 1983;52 (Suppl 1) 115–9.
   Google Scholar